In 2012 MentisCura’s launched the world’s first fully-automated system to use a five minute EEG recording to provide a fast, accurate and reliable assessment of the likelihood that a patient is suffering from a neurological disorder
- powerful, clinically validated diagnostic tool already in use at MentisCura’s clinic
- rapidly gaining market acceptance through validation with leading distributors and key opinion leaders in pharma and academia
MentisCura’s service capitalizes on a decade and €20m of capital and in-kind contribution invested in the development of uniquely powerful, proprietary EEG biomarkers of neurodegenerative disorders
- robust correlation of the patient’s brain state with known positive diagnoses
- world´s most comprehensive EEG database for dementia and cognitive disorders ~5000 records
Alzheimer’s Disease is a clinical expression of synaptic dysfunction, for which electrophysiology serves a robust, fast, affordable and non-invasive method of measurement
The pattern of synaptic dysfunction shows distinct features characteristic of the underlying pathologies of various courses of dementia, such as Alzheimer’s disease, vascular dementia, Lewy body dementia, Parkison’s Disease dementia, delerium and traumatic brain injury.
The importance of measuring the cholinergic system
The cholinergic system is set of biochemical pathways that are strongly associated with forming memory and other cognitive functions in the CNS, based around the neurotransmitter acetylcholine. Many drugs either intentionally or unintentionally up- or down-regulate cholinergic activity.
Measurable changes in cholinergic activity are known to be associated with the pathophysiology of many CNS disorders including Alzheimer’s disease, vascular dementia, Lewy body dementia, Parkison’s Disease dementia, delerium and traumatic brain injury.